Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), has entered into a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb to co-develop next-generation bispecific antibody therapies [1] Group 1: Financial Aspects - HAPO Pharmaceuticals will receive a total payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb chooses to advance all potential projects, HAPO Pharmaceuticals could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties based on future product net sales [1] Group 2: Market Reaction - Following the announcement, HAPO Pharmaceuticals experienced a slight increase at the opening but subsequently declined, with a drop exceeding 5% at one point, and currently showing a decrease of 2.08%, trading at HKD 12.72 with a transaction volume of HKD 36.4509 million [1]
港股异动 | 和铂医药-B(02142)仍跌2% 与百时美施贵宝达成全球战略合作 潜在收益超10亿美元